There are various studies being made about the covid 19 vaccines and their effects on individuals’ health.
The latest one is from the University of Virginia School of Medicine, and it shows that antibody levels in recipients of the Moderna COVID-19 vaccine are slightly higher than recipients of the Pfizer vaccine.
The Jerusalem Post notes the following results of the aforementioned study:
“The difference was mostly noted in relatively older subjects. Researchers took blood samples from 167 vaccinated UVA employees one week to 31 days after their second dose.”
The same notes revealed the following:
“Some 79 were inoculated with the Pfizer vaccine, 88 with the Moderna vaccine. The average age of participants was 42, 38% were 50 or older, and 72% of them were women.”
As the online publication mentioned above notes, this study offered just a small piece to the whole puzzle, but it’s nonetheless very important.
It’s also essential; to note the fact that experts are cautioning against drawing important conclusions about the vaccines’ effectiveness based solely on antibody data.
Just to refresh your memory, the two vaccines mentioned above are using mRNA in order to teach the immune system how it can defend itself against the Covid 19 spike protein, which is unique to the virus.
More side effects are under scrutiny
It’s been just revealed that three new conditions reported by a small number of people after vaccination with COVID-19 shots from Pfizer and Moderna are being studied to assess if they may be possible side-effects – this is what Europe’s drugs regulator said recently, as cited by Reuters press agency.
“Erythema multiforme, a form of allergic skin reaction; glomerulonephritis or kidney inflammation; and nephrotic syndrome, a renal disorder characterised by heavy urinary protein losses,” – all these are being studied by the safety committee of the European Medicines Agency (EMA), according to the regulator.